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Objective—To measure rates of ART use and virologic suppression among perinatally infected 
(PIY) and behaviorally infected youth (BIY) linked to care in the United States, and examine the 
effects of demographic, biomedical, and psychosocial factors on those rates.
Methods—Between 2009–2012, 649 PIY and 1,547 BIY in 20 Adolescent Medicine Trials 
Network for HIV/AIDS Interventions sites completed cross-sectional surveys via audio computer- 
assisted self-interviews. Viral load data were collected from chart abstraction or blood draw.
Results—Overall 82.4% of PIY and 49.1% of BIY reported current ART use. Only 37.0% of 
PIY and 27.1% of BIY were virologically suppressed. Virologic suppression rates did not vary as 
a function of time since HIV diagnosis in either group. Consistent HIV care and no current 
substance abuse were significant correlates of ART use among PIY. These variables and non-
African American race were some factors associated with virologic suppression for PIY (ORs Ps 
< .05). Among BIY, older age, heterosexuals, employment, and education were significantly 
related to ART use (ORs Ps < .05); suppression was related to ART use >6 months, >90% ART 
adherence, and consistent HIV care (ORs Ps < .05). Nearly 75% (n = 498) of non-suppressed 
youth reported unprotected sex in the past 3 months.
Conclusions—There are continued challenges with successfully treating youth even once 
diagnosed and linked to HIV care. Strategies targeting barriers to ART access, use and virologic 
suppression are needed to optimize the impact of the "Treatment as Prevention" paradigm among 
PIY and BIY.
Introduction
Youth ages 13–24 years accounted for 26% of incident HIV infections in 2010 in the United 
States (US), with rates of new HIV infections in young people continuing to rise.1 These 
trends are largely driven by escalating rates among young men who have sex with men 
(YMSM), with an estimated 34% increase in HIV incidence for YMSM from 2006–2009. 
Reducing such disparities is a major focus of the domestic HIV agenda, as reflected in the 
2010 National HIV/AIDS Strategy.3 Furthermore, therapeutic advances in antiretroviral 
therapy (ART) are reducing mortality rates and prolonging survival among perinatal cohorts 
of HIV-infected youth in the US.4,5
The “HIV Treatment Cascade” identifies stages along a continuum of HIV care services, 
with the ultimate goal of viral load suppression.6,7 Of the estimated 1,148,200 persons living 
with HIV in 2009 in the US derived from national surveillance data, 81.9% had been 
diagnosed, 65.8% were linked to care, 36.7% were retained in care, 32.7% were prescribed 
antiretroviral therapy (ART), and 25.3% had a suppressed viral load (<200 copies/mL).5 
Approximately 60–80% of clinical cohorts of persons in care achieve viral suppression.8,9
Among HIV+ youth ages 13–24, only 40.5% have received a diagnosis and 30.6% linked to 
care.9 Further, youth living with HIV/AIDS (YLHIV) have consistently been found to have 
lower rates of viral suppression than older adults and many are not prescribed ART even 
when medically indicated.10,11 In a cohort of HIV-infected young MSM of color, only one-
half of the cohort with CD4 counts ≤350 cells/mm3 had been prescribed ART.12 Data from a 
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large HIV clinical cohort indicated that between 2002–2008 only 69% of behaviorally 
infected youth (BIY) who met clinical criteria (having at least two CD4 measurements <350 
cells/mm3) had initiated ART (compared to 79% of adults).10 Recent CDC data indicate that 
African Americans aged 18–24 displayed the lowest level of viral suppression (18.3%) 
among all groups of individuals in the US.13
In order to achieve the potential promise of the “Treatment as Prevention” strategy (i.e., 
transmission of HIV can be decreased if all infected persons are put on ART—regardless of 
CD4 count),14,15 there is a need to estimate the proportion of youth included in each 
component of the HIV care cascade and characterize barriers and facilitators to retention at 
each stage. Although some information regarding the early (e.g. HIV testing) steps of the 
cascade has been reported for YLHIV,16–19 little attention has focused on youth after 
diagnosis or linkage to care. What has been published for YLHIV has included a literature 
review based on smaller clinical trials or has focused separately on either BIY or PIY, those 
recently diagnosed, or with cohorts that do not reflect current treatment standards. 
Furthermore, little data has looked at time lags between components of the HIV care cascade 
among youth, such as time since testing positive for HIV and ART initiation, or between 
ART uptake and virologic suppression.
Given that youth have not achieved full physical or cognitive maturity, linking and engaging 
HIV-infected youth in care can be challenging.20,21One important barrier to linkage and 
engagement in care is the dearth of HIV-specialty care specifically geared toward adolescent 
developmental needs and the lack of seamless transition procedures to adult-based health 
care.22 YLHIV must navigate traditional adolescent development issues with the added 
burden of living with a highly stigmatized illness while not yet having fully developed the 
internal and social resources to deal with these complex and often competing demands.
The distress associated with living with HIV can impede engagement in care and result in 
high rates of emotional and behavioral problems, including various psychiatric and 
substance use disorders. Both mental health and substance use are linked to decreased ART 
adherence23–25 as well as with engaging in HIV transmission risk behaviors (e.g., 
condomless vaginal/anal intercourse with HIV-negative and status-unknown partners), and 
potentially transmitting HIV to these partners.26–30 Some patient characteristics, such as 
substance use and unstable housing, may elicit concerns among providers about patients’ 
treatment readiness and may be perceived as significant barriers to initiating youth on ART, 
despite the landmark results of HPTN 052 and effects of early ART initiation on decreasing 
HIV infectivity and reducing the likelihood of HIV transmission.15, 31–33 Finally, perinatally 
infected youth (PIY) face additional challenges such as HIV treatment fatigue due to use of 
ART since birth as well as accumulation of resistance mutations resulting in limited ART 
options.33–34 Thus, factors influencing access, utilization of and response to HIV treatment 
as well as engagement and retention in care may differ between PIY and BIY who acquired 
HIV infection as adolescents or young adults.
The primary goal of this paper is to characterize ART use and virologic suppression rates 
among HIV+ youth who have been diagnosed and linked to care in the US. We present data 
on ART use and virologic suppression as a function of length of time since HIV diagnosis 
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and examine demographic, biomedical, and behavioral/ psychosocial correlates of ART use 
and virologic suppression for PIY and BIY. Given the potential biomedical and psychosocial 
differences between the PIY and BIY, our goal was not to directly compare them but rather 
to glean rates and correlates for each in order to inform future intervention development 
targeted toward improving viral suppression for both groups.
Methods
From December 2009 to June 2012, 2,225 YLHIV linked to care at clinics associated with 
the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) were recruited 
to participate in a cross-sectional survey. The 20 clinics were geographically representative 
of the HIV epidemic in the US and Puerto Rico (see Acknowledgements for cities 
represented).
To be eligible, youth had to be: 1) between 12 and 26 years of age (inclusive); 2) HIV-
infected; 3) aware they were HIV-infected; 4) linked to or receiving care in one of the 
ATN’s clinical sites or affiliates (e.g., had at least one clinic visit during the enrollment 
period); and 5) able to understand English or Spanish. The study was approved by the 
Institutional Review Boards at each participating site as well as those from the members of 
the protocol team.
Research staff approached all youth meeting eligibility criteria during one of their scheduled 
clinic visits. After a thorough explanation of the study, staff obtained signed informed 
consent or assent from youth agreeing to participate. Within two weeks of providing 
consent, participants completed audio-computer assisted self-interviews (ACASI) to assess 
psychosocial and health factors, which took approximately 45 to 90 minutes. Participants 
were given a small incentive determined by the sites’ IRB as compensation for their time.
Plasma HIV-1 RNA level (VL) and CD4+ T-cell count data (CD4) obtained within the prior 
six months were abstracted from medical records. The minority (n = 153; 7.0%) of 
participants who did not have VL and CD4 evaluations within six months of the study had 
blood collected at the baseline visit for these measurements. Because of the variability in 
type of VL assay used across the study sites (i.e. Bayer/Siemens Versant HIV-1 RNA 3.0 
(bDNA), Roche Amplicor® HIV-1 Monitor – Standard/Ultrasensitive, Roche COBAS 
AmpliPrep/ COBAS® Taqman® HIV-1 Test, v1.0, 2.0, and Abbott RealTime HIV-1 
Assay), the corresponding assay cut-off for the lower limit of VL (LLD) was used. A 
dichotomous variable to designate virologically suppressed (non-detectable) or virologically 
non-suppressed (detectable) was created. Twenty-nine cases in which the reported viral load 
did not correspond with the LLD of the reported assay were removed. Sensitivity analyses 
on cases in which the assay VL LLD was <400 and cases in which the assays were unknown 
revealed no significant differences in overall rates of detectability and minimized concerns 
about potential bias in the reported VL measurements.
The psychosocial assessment measured 4 primary domains: 1) substance use; 2) mental 
health; 3) sexual behavior; and 4) HIV related adherence. Participants reported demographic 
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information, such as age, birth sex and self-identified gender, race and ethnicity, self-
identified sexual orientation, route of infection, employment, and housing status.
The following measures were utilized:
Mental Health
Mental health issues were assessed with the Brief Symptom Inventory (BSI),35 which yields 
nine primary symptom scales, a global severity index (GSI), and has norms for adolescents, 
adults and gender. The GSI reflects an overall evaluation of a respondent’s 
psychopathological status.
Substance Use
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)36 was used to 
assess substance use behaviors. The ASSIST is an eight-item questionnaire that assesses the 
frequency and consequences of substance use. For current use (past three months) any 
response of 4 (indicating daily or almost daily use) was considered “problematic substance 
use.” The Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT)37 questionnaire is a six-
item measure designed to assess the consequences of alcohol and/or marijuana use by 
adolescents and young adults in clinical settings. Scores of ≥2 are suggestive of problem 
substance use, abuse or dependence.
Sexual Behavior and Activity
Utilizing findings from previous research, ATN scientists developed a 38-item questionnaire 
to assess sexual activity. Participants reported the number of sex partners and the frequency 
of protected and unprotected oral, vaginal, and anal sexual activity with HIV+ and HIV−/ 
unknown status female and male partners during the past three months.
ART Adherence
Utilizing findings from previous research,38 ATN scientists developed a 25-item 
questionnaire to assess medication regimen, frequency of dosing and number and type of 
pills prescribed per day, and number of doses missed in the last 7 days. Adherence was 
dichotomized as < 90% and ≥ 90%. Adherence to scheduled medical appointments with 
HIV care provider over the past 12 months was assessed by self-reported number of missed 
visits. The appointments variable was dichotomized as ≤1 vs. ≥2 missed appointments.
Participants who self reported being on ART and had a current regimen identified during 
medical chart review were classified as “currently on ART.” Those regimens which included 
drugs taken for differential lengths of time or dosing frequencies (QD vs. BID) were 
classified by the drug taken for the longest amount of time and the most frequently 
administered drug. Given that six months on an effective ART regimen should be sufficient 
to result in virologic suppression, suppression rates were only calculated for those youth on 
ART who had been taking them for at least 6 months. Regimens were classified as protease 
inhibitor (PI), non-nucleoside reverse-transcriptase inhibitors (NNRTI), and integrase strand 
transfer inhibitor-based (ISTI) regimens based on the presence of only one these drug 
classes as the anchor drug. Regimens that included both PIs, NNRTIs and/ other classes of 
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drugs, such as Fusion Inhibitors and CCR5 co-receptor antagonists, were classified as 
“Other.” Finally, youth were classified as “eligible” for ART based on CD4 count ≤ 500 
cells/mm3, the threshold at which initiation was uniformly recommended under DHHS 
treatment guidelines active at the time of this study, as well as the more strict guidelines of 
CD4 ≤350 cells/mm3.39,40
Statistical Plan
All analyses were conducted using PASW/SPSS, version 18.0. Participants were classified 
as PIY and BIY; 29 cases where mode of transmission was unknown or related to blood 
transfusion were excluded. Frequencies, means and other measures of central tendencies on 
demographic, biomedical, and psychosocial/behavioral factors were computed for each 
group to describe the sample. Demographic factors used in the analysis consisted of birth 
sex, race, ethnicity, age, sexual orientation, education, employment, and housing status. 
Youth between 12–17 years were defined as younger, while those 18+ years were defined as 
older youth.. Biomedical factors (other than ART use and length of time since diagnosis) 
consisted of ART regimen type, length of time on ART regimen, and regimen dosing. 
Psychosocial factors considered in the analysis included: adherence ≥90%, minimal missed 
HIV care appointments (≤1) over past year, sexual risk over past 3 months (any unprotected 
sex; any unprotected sex with serodiscordant/status unknown partner; and total number of 
sex partners), and problematic and clinically indicative substance use (defined as ≥2 on the 
CRAFFT or ≥ 4 on any substance on the ASSIST), elevated psychological distress (GSI and 
on the BSI).
The rates of ART use and virologic suppression among the entire sample and each subgroup 
(BIY and PIY) were calculated as were rates for each subgroup by time since HIV 
diagnosis. Different categories of length of time since HIV diagnosis were used for BIY and 
PIY because of the significant differences between the two groups in time since HIV 
diagnosis.
Bivariate logistic regression analyses were conducted in order to determine the odds ratio 
(OR) of the demographic, biomedical, and psychosocial/ behavioral correlates with 2 
separate primary outcomes-ART use and virologic suppression. Because of expected 
interactions between many of the variables of interest, multivariate logistic regressions for 
ART use and virologic suppression were conducted with the significant correlates (P < .10) 
from the bivariate analyses for the PIY and BIY groups separately, Race, ethnicity, and 
gender were controlled for in all multivariate models. Given the sample size of each 
subgroup, stratifying allowed for examination of how the different factors under study were 
associated with virologic suppression for PIY and BIY, while also accounting for the 
biomedical and psychosocial differences between the groups. For brevity, only statistical 
findings with P ≤ 0.05 are discussed in the text.
Results
Baseline demographic, biomedical and psychosocial/behavioral characteristics for both PIY 
(n = 649) and BIY (n = 1547) groups are presented in Table 1.
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ART Use and Virologic Suppression among PIY and BIY
While 82.4% of PIY and 49.1% of BIY were currently taking ART, only 37.0% of PIY and 
27.1% of BIY were virologically suppressed (Table 1). Seventy five percent of PIY (n = 
488) and 33.4% (n = 517) of BIY reported taking an ART regimen consecutively for at least 
the past 6 months (Table 2). Virologic suppression rates among these youth were 45.9% for 
PIY and 63.6% for BIY. More than half (n = 504, 56.3%) of our cohort not on ART had 
CD4 count ≤ 500 cells/mm3, and just over a quarter (n = 250; 27.9%) had CD4 ≤350 cells/
mm3.
ART Use and Virologic Suppression among PIY and BIY as a Function of Time since HIV 
Diagnosis
Among PIY, there were significantly greater odds that PIY diagnosed for longer periods of 
time (≥11 years prior) reported taking ART as compared to PIY diagnosed more recently 
(OR: 1.62 (95 CI: 1.07–2.44), P = 0.02). Viral suppression was not related to time since HIV 
diagnosis (0–5 years, 6–10, 11+; years all ORs Ps: ns), even when accounting for continuous 
ART use for ≥6 months.
The likelihood of ART use among BIY diagnosed in the past 12 months (OR: 0.30 (95%: CI 
0.24–0.37), P < 0.001) was lower compared to those with greater time since HIV diagnosis. 
BIY diagnosed 5 or more years prior to enrollment reported greater likelihood of ART use 
(OR: 1.53 (95% CI: 1.15–2.20), P = 0.003) as compared to youth diagnosed more recently 
(0–4 years). Rates of virologic suppression did not follow a linear relationship with time 
since HIV diagnosis among BIY (also when accounting for ART use for ≥6 months). BIY 
diagnosed within the past 2 years displayed greater likelihood of viral suppression as 
compared to youth diagnosed in the past year (OR: 1.69 (95% CI: 1.09–2.60), P = 0.02). 
Conversely, BIY diagnosed within the past 5 or more years displayed significantly lower 
likelihood (OR: 0.60 (95% CI: 0.39–0.90), P = 0.02) of virologic suppression as compared 
to youth diagnosed within the past 4 years.
With the exception of those diagnosed within the past 6–12 months, percent viral 
suppression rates remained between 30–39% across each subsample of youth irrespective of 
time since diagnosis (Table 2).
Multivariate Correlates of ART Use and Virologic Suppression: PIY
In multivariate analyses, ART use among PIY was significantly associated with consistent 
appointment keeping (OR: 0.48) and lack of problematic substance use (OR: 0.55; all ORs 
Ps <.05; see Table 3). Non-African American racial status (OR: 0.56), younger age (12–17; 
OR = 0.61), ART use ≥6 months (OR: 2.48), ART adherence ≥90% (OR: 1.79), not missing 
more than one HIV care appointment over past year (OR: 0.52) and lack of problematic 
substance use (OR: 0.60) were all significant correlates of virologic suppression (all ORs Ps 
< .05; see Table 3).
Multivariate Correlates of ART use and Virologic Suppression: BIY
Among BIY, youth who were male (OR: 0.54), older (18+ years; OR: 2.55), identified as 
heterosexual (0.68), employed (OR: 1.29), and more highly educated (OR: 1.55) each were 
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significantly associated with ART use (all ORs Ps <.05; see Table 4). Virologic suppression 
was significantly associated with greater educational attainment (OR: 1.98), ART use ≥6 
months (OR: 4.65), ≥90% ART adherence (OR: 1.81), and minimal (≤1) missed 
appointments (OR: 0.50; all ORs Ps < .05; see Table 4).
Virologic Suppression and Behavioral (Sexual) Risk Behaviors
A significant proportion of youth (30.5%; n = 669) in the sample engaged in unprotected sex 
over the past 3 months. Two-thirds (74.4%; n = 498) of youth who engaged in unprotected 
sex had detectable viremia, including 76.1% (n = 509) who reported having unprotected sex 
with a serodiscordant or serostatus unknown partner in the past three months.
Discussion
To our knowledge, this is the first study to report on ART use and virologic suppression 
rates among a large national representative sample of both PIY and BIY linked to HIV care 
at 20 adolescent medicine clinics the US. Several key findings are worth highlighting. Only 
about 1/3 of youth (37.0% of PIY and 27.1% of BIY) currently linked to care at ATN 
clinical sites were virally suppressed. Even after accounting for ART use for at least six 
months, the rates of suppression are unacceptably low (45.9% for PIY and 63.6% for BIY). 
This is particularly troubling since our sample was linked to, and receiving care at, 
adolescent medicine clinics specializing in HIV care and did not include the youth unaware 
of their HIV diagnosis. Furthermore, is also not clear that suppression rates are in any 
meaningful way a function of length of time since HIV diagnosis among youth in our 
sample, suggesting continuing psychosocial and likely structural challenges. This highlights 
the public health imperative to assist youth to access and adhere to ART and ultimately 
achieve virologic suppression.
Rates of ART use in this sample are consistent with findings from other studies. A majority 
of PIY in this sample reported current ART use, which concords with increases in ART 
prescription rates over time (2002–2010) in a cohort of 521 PIY in the US.19 Less than half 
of BIY in our sample were currently taking ART, which is consistent with research from a 
smaller multi-site clinical cohort of 268 BIY (age 18–29) in which 31.3% of youth meeting 
clinical criteria had not initiated ART.8 Depending on the treatment guidelines active at the 
time of study or currently used (CD4 < 500 cells/mm3 vs. CD4≤350),39,40 25.7–56.3% of 
youth in our sample who were eligible for ART were not taking it. Future research needs to 
ascertain if these youth, particularly BIY, were ever offered or prescribed ART, as well as 
the reasons they may have rejected ART use, such as financial barriers, stigma associated 
with HIV and/or ART use, treatment expectancies, etc. It bears mentioning that although the 
Patient Protection and Affordable Care Act offers great promise for the expansion of health 
coverage among young adults in particular (i.e., remaining on their parents’ insurance 
through age 26), there are data suggesting that even in universal access to no-cost care, late 
initiation of ART occurs among up to 40% of HIV+ men and women aged 18 to 29 years in 
Canada.41 Thus, the delays in the initiation of ART or barriers to ART use may be beyond 
purely economic and also reflect a confluence of cultural, psychosocial, social, and 
structural etiologies that require further delineation.
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One additional factor requiring further investigation is the degree to which providers may be 
hesitant to prescribe ART for those individuals whom they perceive as not being ready to 
initiate or have refused treatment.31,32 Given the risks of resistance mutations associated 
with ART nonadherence42–43, providers may opt to delay ART until they identify 
appropriate “treatment readiness” among patients. This potential provider bias or concern of 
not wanting to prescribe ART to youth they deem potentially non-adherent or less 
“responsible” and rigorous in their health care behaviors and scheduling demands of ART is 
partially supported by the findings that consistent appointment keeping, lack of symptomatic 
substance use, older age, employment, and higher levels of educational attainment were 
significantly related to ART use among both BIY and PIY. Some initial promising tools to 
assess treatment readiness among individuals with HIV are being developed.44,45 Future 
research to validate measures of patient readiness for treatment, understand factors related to 
treatment decisions among providers, and develop provider-focused interventions meant to 
facilitate youth’s treatment readiness for ART is needed.
There were no racial differences among BIY in our sample with respect to virologic 
suppression rates, which is consistent with other studies reporting no significant racial or 
ethnic differences in viral load suppression rates after controlling for ART use.7,46 However, 
African-American PIY in our sample were more likely to be virologically non-suppressed, 
even after controlling for ART use, which replicates other findings on black race being 
independently associated with higher likelihood of detectable viremia among PIY19 and 
overall racial health disparities with respect to virologic outcomes among African-American 
youth and younger adults.11,47 Length of time since HIV diagnosis is a key difference 
between PIY and BIY and there may be multi-level or systemic factors leaving African-
American PIY with prolonged disease particularly vulnerable to non-suppression. One 
possibility may be poor suppression rates due to prior inferior prior HIV therapeutics and 
multiple regimens.48 Future research needs to examine this and others potential factors 
further. Furthermore, the degree to which advances in HIV treatment can potentially reduce 
racial health disparities requires further examination, as does the identification and 
dissemination of the core components of HIV service delivery programs that effectively 
eliminate HIV-related disparities.
Once diagnosed, many youth continue to engage in sexual and drug use behaviors that can 
contribute to the risk for ongoing transmission and acquisition of other STDs. Consistent 
with previous studies,26–30 a large proportion (30.5%; n = 669) of our sample reported 
engaging in unprotected sex, including nearly 75% (74.4%; n = 498) of viremic youth who 
reported having unprotected sex with a serodiscordant or serostatus unknown partner in the 
past three months. This has clear public health implications for ongoing transmission of HIV 
and highlights the critical need for secondary HIV prevention and/or risk reduction 
interventions in combination with increased provision of ART targeting YLHIV. The HIV 
secondary preventive interventions should target mental health and substance use issues as 
well given the high prevalence rates for each among YLHIV as well as the fact that they are 
related to ongoing risk transmission behavior.23–28
Our findings must be interpreted in light of certain limitations. Since our data are cross-
sectional, it was not possible to assess causality or longitudinal trajectories of ART use and 
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virologic suppression rates. In addition, some of our data were derived solely by self-report, 
such as adherence to ART regimens, which could account for the lower rates of virologic 
suppression than the self-report data would have predicted. However, the accurateness of 
self-report, and ACASI specifically, as they relate to the reporting of sexual behavior among 
youth is more established,49–50 limiting some concerns about the relationship between self-
reported behavior and relevant clinical outcomes. Moreover, the authors are not aware of 
any research suggesting differential self-report reporting outcomes for African-American as 
compared to other racial and ethnic groups, and as such it is likely that the racial differences 
seen in the study represent a finding that is not explained solely by self-report methodology. 
Future research should incorporate multi-informant reporting (i.e., patient, caregiver/parent, 
physician, and objective measurement, such as electronic monitoring) to more 
comprehensively and accurately assess participant behavior. Further, the majority (93%) of 
the virologic suppression data were not collected at the same time as the ACASI interview 
(although always within 6 month period) which could also have led to somewhat higher 
rates of detectable viral load among those recently diagnosed and not yet given ART. 
Finally, the authors did not obtain data on caregiver serostatus or role in HIV care and we 
relied on “time since diagnosis” as the only available proxy for engagement in care
Our findings highlight the continued challenges of successfully treating youth even once 
they are linked to HIV medical care. Focused strategies that target multiple barriers to ART 
access, uptake, use, and ultimately the achievement of virologic suppression are needed in 
order to fully optimize the potential impact of the “Treatment as Prevention” paradigm 
among PIY and BIY.
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Table 1
Demographic, Biomedical, and Psychosocial Characteristics of Perinatally and Behaviorally Infected HIV+ 
Youth (n=2196)
Perinatal Infected (n = 649)
No. (%) or Mean ± SD
Behavioral Infected (n =1547)
No. (%) or Mean ± SD
Age, y 17.89 ± 2.9 21.18 ±2.1
Sex, Gender*
  Males 288 (44.4) 1175 (76.0)
  Females 356 (54.9) 368 (23.8)
  Transgender 2 (0.3) 54 (3.5)
  No answer/Missing 5 (.8) 4 (.3)
Race
  African American on Hispanic 425 (65.5) 1043 (67.4)
  White 81 (12.5) 191 (12.3)
  Mixed 71 (10.9) 173 (11.3)
  Asian/Other 53 (8.2) 131 (8.5)
  No answer/missing data 19 (2.9) 9 (0.6)
Latino/Hispanic Ethnicity 127 (19.6) 304 (19.7)
Sexual Orientation
  Heterosexual 568 (87.5) 417 (27.0)
  Gay/Lesbian 27 (4.2) 837 (54.1)
  Bisexual 43 (6.6) 225 (14.5)
  Questioning/Queer/Other 5 (0.8) 58 (3.8)
  No answer/missing data 6 (0.9) 10 (0.6)
Highest Level of Education
  No High School Completion 331 (51.0) 422 (27.3)
  High School Graduate/GED 195 (30.0) 562 (36.3)
  Some College/College or Technical School Graduate 101 (15.6) 554 (35.8)
  No answer (missing data) 22 (3.4) 9 (0.6)
Currently Employed 128 (19.7) 596 (38.5)
Stably Housed 615 (94.8) 1441(93.1)
Length of Time since HIV Diagnosis (Days) 4133.29 ± 2079.0 737.93 ±715.8
  0–12 mos. 28 (4.3) 621 (40.1)
  13–24 mos. 23 (3.5) 304 (19.7)
  25+ mos. 598 (92.1) 622 (40.2)
CD4 Cell Count (Range) 540.84 ± 337.3 (1–2320) 503.26 ± 241.0 (4–1670)
VL
  Suppressed (Undetectable) 240 (37.0) 420 (27.1)
  Nonsuppressed (Detectable) 390 (60.1) 1105 (71.4)
  Missing 19 (2.9) 22 (1.4)
Current ART Use 535 (82.4) 759 (49.1)
ART for ≥6 months 488 (75.2) 517 (33.4)
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Perinatal Infected (n = 649)
No. (%) or Mean ± SD
Behavioral Infected (n =1547)
No. (%) or Mean ± SD
Type of Regimen (ART)
  PI 305 (57.0) 384 (50.6)
  NNRTI 100 (18.7) 338 (44.5)
  Integrase 3 (0.56) 22 (2.9)
  Other** 127 (23.7) 15 (2.0)
Adherence to ART (last 7 days) 85.19 ±23.4 87.5 (23.0)
% ≥90 Adherence 310 (57.9) 477 (62.9)
Missed # of HIV Care Appts. over past 12 months (M, SD) 1.47 ±3.8 1.70 ±3.0
Sex Risk
  Any unprotected sex 90 (13.9) 579 (37.4)
  Any unprotected sex with serodiscordant/status unknown partner 77 (11.9) 405 (26.2)
  Total number of sex partners in past 3 mos. (≥2) 123 (19.0) 803 (51.9)
ASSIST Current (≥4 on any substance) 105 (16.2) 661 (42.7)
CRAFFT (≥2 as clinically significant) 231 (35.6) 973 (62.9)
Global Severity Index (clinically indicative) on BSI*** 142 (21.9) 804 (52.0)
Note: VL = viral load; ART = antiretroviral therapy; PI = protease inhibitor; NNRTI = non-nucleoside reverse-transcriptase inhibitors; Integrase = 
integrase strand transfer inhibitor-based regimens; ASSIST= The Alcohol, Smoking and Substance Involvement Screening Test; CRAFFT=Car, 
Relax, Alone, Forget, Friends, Trouble (keywords in a screening questionnaire to identify at-risk teen substance abusers; BSI = Brief Symptom 
Inventory).
*
In Table 1, the male, female, and transgender variable is defined by the gender that individuals currently endorse for themselves.
**
Regimens that included both PIs, NNRTIs and other classes of drugs, such as Fusion Inhibitors and CCR5 co-receptor antagonists, were 
classified as “Other.”
***
= Clinically indicative: males ≤19, GSI ≥1.71; females ≤ 19, GSI≥1.59; males ≥20, GSI ≥0.58; females ≥20, GSI ≥0.78)
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Table 3
Multivariate Analyses of Current ART Use and Virologic Suppression among Perinatally Infected Sample 
(n=649)




  Birth Sex (male vs. female) .87 .55–1.36 .530
  Race (other vs. African-American) .66 .36–1.20 .169
  Ethnicity (other vs. Latino) 1.05 51–2.15 .897
  Age (12–17 vs. 18+ years) .66 ..41–1.06 .085
  Missed Appt. (≤1 vs. vs. 2+) .48 .30–.76 .002
  ASSIST Current (≥4 on any substance) (no/yes) .55 .32–.95 .033
VL Suppression
  Birth Sex (male vs. female) 1.04 .69–1.58 .852
  Race (other vs. African-American) .56 .34–.95 .030
  Ethnicity (other vs. Latino) .64 .35–1.16 .141
  Age (12–17 vs. 18+ years) .61 .40–.92 .018
  Sexual Orientation (heterosexual vs. gay/bisexual/other) .52 .26–1.05 .068
  PI Regimen vs. All .67 .41–1.10 .112
  NNRTI Regimen vs. All 1.81 .98–3.36 .058
  ART ≥6 months (no/yes) 2.48 1.09–5.63 .030
  Missed Appt. (≤1 vs. vs. 2+) .52 .32–87 .012
  ART Adherence ≥90% (no/yes) 1.79 1.17–2.72 .007
  CRAFFT (≥2 as clinically significant) (no/yes) .60 .38–.95 .030
Note: ART = antiretroviral therapy; VL = viral load; PI = protease inhibitor; NNRTI = non-nucleoside reverse-transcriptase inhibitors; 
CRAFFT=Car, Relax, Alone, Forget, Friends, Trouble (keywords in a screening questionnaire to identify at-risk teen substance abusers; BSI = 
Brief Symptom Inventory).
*
For the purposes of these multivariate analyses, the authors used “Birth Sex” (male or female). Authors didn’t run transgender as a separate 
correlate simply because the numbers were very low and thus would have been difficult with such small numbers to find any meaningful 
differences.
**
= Clinically indicative: males ≤19, GSI≥1.71; females ≤ 19, GSI≥1.59; males ≥20, GSI ≥0.58; females ≥20, GSI ≥0.78).
p < .05 bolded.
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Table 4
Multivariate Analyses of Current ART Use and Virologic Suppression among Behaviorally Infected Sample 
(n = 1547)




  Birth Sex (male vs. female) .54 .38–.77 .001
  Race (other vs. African-American) 1.15 .88–1.49 .311
  Ethnicity (other vs. Latino) 1.12 .82–1.52 .481
  Age (12–17 vs. 18+ years) 2.55 1.44–4.51 .001
  Sexual Orientation (heterosexual vs. gay/bisexual/other) .68 .49–.95 .023
  Completed High School (no/yes) 1.55 1.20–1.99 .001
  Employment (none vs. part/full time) 1.29 1.04–1.61 .021
VL Suppression
  Birth Sex (male vs. female) .93 .60–1.44 .750
  Race (other vs. African-American) 1.03 .67–1.59 .894
  Ethnicity (other vs. Latino) 1.35 .81–2.24 .245
  Completed High School (no/yes) 1.98 1.29–3.02 .002
  ART ≥6 months (no/yes) 4.65 3.17–6.81 .001
  Missed Appt. (≤1 vs. vs. 2+) .50 .35–.72 .001
  ART Adherence ≥90% (no/yes) 1.81 1.27–2.58 .001
Note: ART = antiretroviral therapy; VL = viral load
p < .05 bolded.
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